DEBORAH DOUGHERTY: Open Payments
NPI 1760487821 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,498 in 128 payments from 11 companies in 2025. Trend: 2023 $779 · 2024 $1,436 · 2025 $2,498
Food & beverage: $2,498
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $746 |
| Otsuka America Pharmaceutical, Inc. | 20 | $384 |
| ABBVIE INC. | 19 | $272 |
| E.R. Squibb & Sons, L.L.C. | 18 | $271 |
| Lundbeck LLC | 11 | $221 |
| Vanda Pharmaceuticals Inc. | 12 | $195 |
| Alkermes, Inc. | 7 | $187 |
| Neurocrine BioSciences, Inc. | 5 | $117 |
| Supernus Pharmaceuticals, Inc. | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
Products named: CAPLYTA, REXULTI, COBENFY, VRAYLAR, ARISTADA, FANAPT, ABILIFY ASIMTUFII, INGREZZA.
Industry payments across VA — which companies pay providers there.
